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Thecombinationofliposomeswithpolymericscaﬀoldscouldrevolutionizethecurrentstateofdrugdeliverytechnology. Although
liposomes have been extensively studied as a promising drug delivery model for bioactive compounds, there still remain major
drawbacks for widespread pharmaceutical application. Two approaches for overcoming the factors related to the suboptimal
eﬃcacy of liposomes in drug delivery have been suggested. The ﬁrst entails modifying the liposome surface with functional
moieties, while the second involves integration of pre-encapsulated drug-loaded liposomes within depot polymeric scaﬀolds.
This attempts to provide ingenious solutions to the limitations of conventional liposomes such as short plasma half-lives,
toxicity, stability, and poor control of drug release over prolonged periods. This review delineates the key advances in composite
technologies that merge the concepts of depot polymeric scaﬀolds with liposome technology to overcome the limitations of
conventionalliposomes for pharmaceutical applications.
1.Introduction
Over the past few decades, liposomes have received wide-
spread attention as a carrier system for therapeutically
active compounds, due to their unique characteristics such
as capability to incorporate hydrophilic and hydrophobic
drugs, good biocompatibility, low toxicity, lack of immune
system activation, and targeted delivery of bioactive com-
pounds to the site of action [1–4]. Additionally, some
achievements since the discovery of liposomes are controlled
size from microscale to nanoscale and surface-engineered
polymer conjugates functionalized with peptide, protein,
and antibody [5, 6]. Although liposomes have been exten-
sively studied as promising carriers for therapeutically active
compounds, some ofthemajor drawbackfor liposomesused
in pharmaceuticsare therapiddegradationduetothereticu-
loendothelialsystem (RES)and inability to achieve sustained
drug delivery over a prolonged period of time [7]. New
approaches are needed to overcome these challenges. Two
polymeric approaches have been suggested thus far. The ﬁrst
approach involves modiﬁcation of the surface of liposomes
with hydrophilic polymers such polyethylene glycol (PEG)
while the second one is to integrate the pre-encapsulated
drug-loaded liposomes within depot polymer-based systems
[3]. A study conducted by Stenekes and coworkers [8]
reported the success of using temporary depot of polymeric
materials to control the release of the loaded liposomes for
pharmaceutical applications. This achievement leads to new
applications, which requires collaborative research among
pharmaceuticals,biomaterials,chemistry, molecular, andcell
biology.Numerousstudiesinthiscontexthavebeenreported
in the literature dealing with temporary depot delivery sys-
tem to control the release of pre-encapsulated drug-loaded
liposomes[9–12].Thissystemwasdevelopedtointegratethe
advantages while avoid the disadvantages of both liposome-
based and polymeric-based systems. The liposome-based2 Journal of Drug Delivery
systems are known to possess limitations such as instability,
short half-life, and rapid clearance. However, they are
more biocompatible than the polymer-based systems [13].
On other hand, the polymer-based systems are known to
be more stable and provide improved sustained delivery
compared to liposome-based systems. However, one of the
major setbacks is poor biocompatibility which is associated
with loss of the bioactive (i.e., the drug) during fabricating
conditions such as heat of sonication or exposure to organic
solvents[3,11].The beneﬁtsofa compositesystem,however,
include improvement of liposome stability, the ability of the
liposome to control drug release over a prolonged period of
time, and preservation of the bioactiveness of the drugs in
polymeric-based technology. In addition, increased eﬃcacy
may be achieved from this integrated delivery system when
compared to that of purely polymeric-based or liposome-
based systems. The aim of this article therefore, is to review
the current liposome-based and polymeric-based technolo-
gies, as well as the integration of liposome-based technology
within temporary depot polymeric-based technology for
sustained drug release. The discussion will focus on diﬀerent
types of liposome-based technology and depot polymeric
scaﬀold technologies, various methods for embedding drug-
loaded liposomes within a depot, and various approaches
reported to control the rate of sustained drug release within
depot systems over a prolonged period of time.
2.Liposome-Based Technology
A liposome is a tiny vesicle consisting of an aqueous core
entrapped within one or more natural phospholipids form-
ing closed bilayered structures (Figure 1)[ 5]. Liposomes
have been extensively used as potential delivery systems
for a variety of compounds primarily due to their high
degree of biocompatibility and the enormous diversity of
structures and compositions [14, 15]. The lipid components
ofliposomesarepredominantlyphosphatidylcholine derived
from egg or soybean lecithins [15]. Liposomes are biphasic
a feature that renders them the ability to act as carriers
for both lipophilic and hydrophilic drugs. It has been
observed that drug molecules are located diﬀerently in the
liposomal environment and depending upon their solubil-
ity and partitioning characteristics, they exhibit diﬀerent
entrapment and release properties [15, 16]. Lipophilic drugs
are generally entrapped almost completely in the lipid
bilayersof liposomes and since they are poorly water soluble,
problems like loss of an entrapped drug on storage are rarely
encountered. Hydrophilic drugs may either be entrapped
inside the aqueous cores of liposomes or be located in the
external water phase. Noteworthy is that the encapsulation
percentage of hydrophilic drugs by liposomes depends on
the bilayer composition and preparation procedure of the
liposomes [17, 18].
SinceliposomediscoverybyBanghamandcoworkers[5],
severaldiﬀerentembodimentsofliposome-basedtechnology
have been developed to meet diverse pharmaceutical criteria
[7]. Liposome-based technology has progressed from the
ﬁrst generation “conventional vesicles,” to stealth liposomes,
targeted liposomes, and more recently stimuli-sensitive lipo-
somes [3, 19]. Essentially, liposomes are classiﬁed according
to their size range, being 50–5000nm in diameter. This
resultedinto twocategoriesofliposomesnamelymultilamel-
lar vesiclesand unilamellar vesicles [19]. Unilamellar vesicles
consist of single bilayer with a size range of 50–250nm while
multilamellar vesicles consist of two or more lipid bilayers
with a size range of 500–5000nm [3, 20].
2.1. Conventional Liposomes. Conventional liposome-based
technology is the ﬁrst generation of liposome to be used
in pharmaceutical applications [3, 21, 22]. Conventional
liposome formulations are mainly comprised of natural
phospholipids or lipids such as 1,2-distearoryl-sn-glycero-
3-phosphatidyl choline (DSPC), sphingomyelin, egg phos-
phatidylcholine, and monosialoganglioside. Since this for-
mulation is made up of phospholipids only, liposomal
formulations have encountered many challenges; one of the
major ones being the instability in plasma, which results
in short blood circulation half-life [7, 23–25] Liposomes
that are negatively or positively charged have been reported
to have shorter half-lives, are toxic, and rapidly removed
from the circulation [23, 26, 27]. Several other attempts
to overcome these challenges have been made, speciﬁcally
in the manipulation of the lipid membrane. One of the
attempts focused on the manipulation of cholesterol. Addi-
tion of cholesterol to conventional formulations reduces
rapid release of the encapsulated bioactive compound into
the plasma [28]. Furthermore, studies by Tran and cowork-
ers [29] demonstrated liposome stability after addition
of “helper” lipids such as cholesterol and 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE). Harashima and
coworkers [20] demonstrated thatphagocytosisofliposomes
was due to the size of the liposome formulation. Larger size
ormultilamellar liposomeswith a size range of500–5000nm
were the ﬁrst to be eliminated from the systemic circulation.
Nanosized liposomes or small unilamellar vesicles with a
size range of 20–50nm were only developed later [7, 20,
30]. The following drugs: Ambisone, Myocet, Daunoxome,
and Daunorubicin have received clinical approval using
conventionalliposometechnologies[31–33].Althoughsmall
unilamilar liposomes were reported to have potential for a
decreased microphage uptake, insuﬃcient drug entrapment
is still a major disadvantage. On the basis of this study,
the success of cholesterol and others phospholipids did not
completely overcome the major challenges.
2.2. Stealth Liposomes. Stealth liposome technology is one
of the most often used liposome-based systems for delivery
of active molecules [3, 22]. This strategy was developed to
overcome most of the challenges encountered by conven-
tional liposome technology such as the inability to evade
interception by the immune system, toxicity due to charged
liposomes, low blood circulation half-life, and steric stability
[7, 22, 26]. Stealth liposome strategy was achieved simply by
modifying the surface of the liposome membrane, a process
that was achieved by engineering hydrophilic polymer
conjugates [34]. The employed hydrophilic polymers wereJournal of Drug Delivery 3
(a) (b) (c)
(d) (e) (f)
Figure 1: Schematic representation of liposome-based systems. (a) Conventional liposomes. (b) Stealth liposome coated with a polymeric
conjugate such as PEG. (c) Stealth liposome coupled with a functionalized ligand. (d) Liposome with a single ligand and antibody.
(e) Duplicated ligand with repeated peptide sequence. (f) Liposome loaded with perﬂuorocarbon gas (adapted from Zucker et al. [16]).
eithernatural or synthetic polymers such polyethylene glycol
(PEG), chitosan, silk-ﬁbroin, and polyvinyl alcohol (PVA)
[35–38]. Several properties that would add advantages to
polymeric conjugate were considered such as high biocom-
patibility, nontoxicity, low immunogenicity, and antigenicity
[3, 35]. Although the majority of hydrophilic polymers
meet the above criteria, PEG remains the most widely used
polymer conjugate. It is speciﬁcally employed to increase the
hydrophilicityoftheliposome surface via across-linked lipid
[39, 40]. PEGylated liposomal doxorubicin (DOXIL/Caelyx)
is the exceptional example of stealth liposome technology to
beapprovedbyboththeUSAFoodandDrugAdministration
(FDA) and Europe Federation [41]. Although prominent
results were achieved from this model such as reduction
of macrophage uptake, long circulation, and low toxicity,
passive targeting is still amajor disadvantage since liposomes
can deliver active molecules not only to abnormal cells but
also to sensitive normal cells [7, 42]. Figure 2 depicts a
schematic for a PEGylated liposome.
2.3. Targeted Liposomes. Targeted liposome based system
was suggested after conventional stealth liposome failed
to evade uptake of active molecules by sensitive normal
cells or nonspeciﬁc targets in vivo [43, 44]. Unlike stealth
liposome, site-speciﬁc targeting liposome has been engi-
neered or functionalized with diﬀerent types of targeting
moieties such antibodies, peptide, glycoprotein, oligopep-
tide, polysaccharide, growth factors, folic acid, carbohydrate,
and receptors [45–50]. In addition, targeted ligand can
further increase the rate of liposomal drug accumulation in
the ideal tissues/cells via overexpressed receptors, antigen,
and unregulated selectin [51–55]. Peptides, protein, and
antibodies have been most extensively studied as a ligand
for directing drug-loaded liposomes into sites of action, due
to their molecule structures, which are essentially composed
of known amino acid sequences. Furthermore, it has been
postulated that ligands can be conjugated onto pegylated
liposomes via diﬀerent types of coupling methods, such
as covalent and noncovalent binding. Covalent coupling
occurs when novel ligands are indirectly engineered on
the surface of liposome through a hydrophobic anchor
via thioether, hydrazone bonds, avidin–biotin interaction,
cross-linking between carboxylic acids and/or amines [56].
Noncovalent coupling is observed when novel ligands are
directly added to the mixture of phospholipids during the
liposomal formulation [15]. Li et al. [48] attempted to
generate dual ligand liposome conjugates aimed at targeting
multiple receptor types on the cell surface receptors. Ex vivo
studiesdemonstrated thesuccessofthe dual ligand approach4 Journal of Drug Delivery
Figure 2: Schematic depicting of a stealth PEGylated liposome
(Adapted from Rai et al. [58]).
in improving the selectivity when compared to a single
ligand approach. In another study, Ying and coworkers [50]
formulated dual targeted liposomes with various targeted
moieties such as p-aminophenyl-α-D-manno-pyranoside
(MAN) and transferrin (TF). The study was conducted
both ex vivo (in C6 glioma cells) and in vivo (in C6
brain glioma-bearing rats). The following were compared:
free daunorubicin, daunorubicin liposomes, daunorubicin
liposomesmodiﬁedwithMAN,anddaunorubicinliposomes
modiﬁed with TF as the controls, and daunorubicin lipo-
somes modiﬁed with MANand TF.Daunorubicinliposomes
modiﬁed with dual ligands such as MAN and TF showed
a more signiﬁcant increase in therapeutic eﬃcacy, when
compared with the drug alone, drug-loaded liposome, or
single ligand modiﬁed surface of the liposome. However,
the eﬃcacy of these approaches faces limitations because
protein circulation and gene expression cannot be sustained
for long periods of time [7]. Doxorubicin-loaded liposomes
were surface engineered with monoclonal antibody and are
now commercially available [57]. The overall advantage of
this model of liposome is an increase in active molecules or
drug reach targeted cells via endocytosis [7].
In another study, Nallamothu and coworkers [59]
demonstrated the usefulness of Combretastatin A4 as novel
antivascular agent. This compound portrays its anticancer
activity by inducing irreversible vascular shutdown in solid
tumors [60]. Despite its anticancer potential, the drug
has shown to have several undesirable side eﬀects to the
underlying normal tissues [61]. These problems may be
alleviatedbytargetingthedrugspeciﬁcally tothesolidtumor
vasculature. Studies have shown that certain cell adhesion
molecules such as αvβ3 integrin receptors are overexpressed
on actively proliferating endothelium of the tumor vascu-
lature [62, 63]. These surface markers discriminate tumor
endothelial cells from the normal endothelial cells and can
be used as a target for antivascular drug delivery [59].
Nallamothu and coworkers [59] could demonstrate that
peptides with Arginine-Glycine-Aspartine (A-G-A) amino
A-G- Apeptide
PEG
Liposome bilayer
Figure 3: A schematic representation of the targeted liposome
delivery system depicting the cyclic RGD peptides that targets the
αvβ3 integrin receptors on the vascular tumor cells (adapted from
Nallamothuet al. [59]).
acid sequence constrained in a cyclic polyethylene-glycol
(PEG)-based liposome framework can bind to the αvβ3
integrin receptors. Basing on this analogy, they could design
a targeted liposome delivery system for combretastatin A4
with cyclic (RDG) peptides as targeting ligands (Figure 3).
Targeting of combretastatin A4 to irradiated tumors using
this delivery system resulted into signiﬁcant tumor growth
delay [59].
2.4. Other Types of Liposomes
2.4.1. Virosomes and Stimuli-Responsive Liposomes. Liposo-
mal technologies, such as conventional, stealth, and targeted
liposomes have already received clinical approval [64, 65].
New generation types of liposome have been developed to
increase bioactive molecule delivery to the cytoplasm by
escape endosome [1, 66, 67]. New approaches that employ
l i p o s o m e sa sp h a r m a c e u t i c a lc a r r i e r sa r ev i r o s o m e sa n d
stimuli-type liposomes. The stimulating agents in this case
include pH, light, magnetism, temperature, and ultrasonic
waves. A virosome (Figure 4) is another type of liposome
formulation. It comprises noncovalent coupling of a lipo-
some and a fusogenic viral envelop [68]. A stimuli-sensitive
liposome is a type of liposome that generally depends on
diﬀerent environmental factors in order to trigger drug, pro-
tein, and genedelivery.A study conductedby Schroederet al.
[69], Liu and coworkers [67], and Lentacker and coworkers
[70] demonstrated that the exposure of the liposome loaded
with perﬂuorocarbons gas to ultrasound waves triggered
drug and gene delivery into the cytoplasm of the targeted
cells through cell membrane pores. Their data demonstrated
that the liposome-loaded magnetic agents triggered drug
deliverytothespeciﬁcsite invivo,usingan externallyapplied
magnetic ﬁeld. The enhancement of endosomal release of
drug-loaded liposome into the cytoplasm was also reportedJournal of Drug Delivery 5
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Figure 4: Aschematicrepresentation ofavirosome(source:Pevion
Biotech Ltd. [73]).
to be inﬂuenced by the utilization of pH-sensitive liposomes
or by attachment of pH-sensitive fusogenic peptide ligands
[1, 71, 72]. Most recently, a review article published by
Chen and coworkers [4] described the generation of stable
liposomes utilizing lyophilization techniques, which may be
a promising future model for liposome production.
2.4.2.Gene-BasedLiposomes. Thecharacterization ofhuman
genomecoupledwith recombinant DNAtechnologyhas cre-
ated opportunities for gene therapy that never existed before
[74]. Candidate diseases for such technology include cancer
[75], arteriosclerosis [76], cystic ﬁbrosis [77], haemophilia,
sickle cell anaemia, and other genetic diseases. Ideally, the
administration of the gene of interest should result in
the expression of the therapeutic protein. However, the
delivery of the large anionic bioactive DNA across cell has
been one of the most diﬃcult endeavors. DNA is easily
degraded by circulating and intracellular deoxyribonucle-
ases. Notwithstanding, it must also be delivered intact across
the cell and nucleolar membranes to the nucleus [74].
Liposomes have thus proved to achieve eﬃcient intracellular
delivery of DNA [78, 79]. Such liposomes are prepared
from phospholipids with an amine hydrophilic head group.
The amines may be either quaternary ammonium, tertiary,
secondary, or primary, and the liposomes prepared in this
way are commonly referred to as cationic liposomes, since
they possess a positive surface charge at physiological pH.
The use of cationic liposomes as gene delivery systems was
ﬁrstly enforced in the late 1980s when in vitro studies by
Felgner and coworkers [80] could demonstrate that the
complexation of genes with liposomes may promote gene
uptake by cells in vitro. Since then, cationic liposomes of
varying description have been used to promote the cellular
uptakeof DNAwith resultant therapeutic proteinexpression
by various organs in vivo. Figure 5 depicts a schematic
representation of a DNA-liposome complex.
Although the experimental data have demonstrated that
cationic liposomes can facilitate the transfer of DNA into
live mammalian cells, there are still major problems that
need to be overcome in order to eﬀectively achieve the
goal. These include a reduction in the rapid clearance
of cationic liposomes and the production of eﬃciently
targetedliposomes. Atthecellularlevel,theproblemsmay be
Figure 5: A schematic representation of a DNA-liposome complex
(adapted from Uchegbu [74]).
overcomebyimprovingreceptormediateduptakeemploying
appropriate ligands. The endowment of liposomes with
endosomal escape mechanisms, coupled with more eﬃcient
translocation of DNA to the nucleus and the eﬃcient
dissociation of the liposome complex just before the entry
of free DNA into the nucleus might provide an optimal
cornerstone solution to the problem. This proposition is
depicted in Figure 6.
3.TemporaryDepot Polymeric-Based Systems
forLiposomalCoupling
Polymer-based systems, such as hydrogel or prefabricated
scaﬀolds have been used as depots for drugs, regenerative
cells, protein, growth factor, and pre-encapsulated drug-
loaded liposome for sustained release [8, 12, 81–85]. Various
polymers have been researched for this application based
on their fundamental properties such as biodegradability,
biocompatibility, nontoxicity, and the noninﬂammatory
tendency. Natural and synthetic biodegradable polymeric
systems such chitosan, collagen, gelatin, ﬁbrin, alginate,
dextran,carbopol,andpolyvinylalcoholhavebeenemployed
as temporary depot-forming agents since they meet most of
the above requirements [11, 84, 86, 87].
3.1. Injectable Polymeric Scaﬀolds. The strategy for gener-
ating an ideal depot for an active compound or bioactive
molecule-loaded liposome with the beneﬁt of in local drug
retention and sustained release over prolonged time has
recently received much attention in both pharmaceutical
and bioengineering research [85, 88]. The in-situ forming
injectable polymer was among the most successful models,
since it was able to encapsulate protein and/or bioactive
molecules or function as a pre-encapsulated drug-loaded
liposomal formulation that was in liquid form [89, 90].
This solution or suspension mixture could then be injected
into the target organ with a needle to form a semisolid6 Journal of Drug Delivery
scaﬀold and ﬁnally an implant. The success in shifting from
liquid formulation to semisolid and ﬁnally to an implant
was a result of various desirable polymeric properties and
stimulating agents such as water, light, temperature, and pH,
that facilitated such processes within the polymer such as
precipitation,cross-linking, and polymerization [88, 91–93].
Since the majority of hydrogels were composed of natural
or synthetic biodegradable polymers, bioactive molecules
were released via passive diﬀusion, matrix pore formation,
or polymeric degradation [94–97]. Furthermore, semisolid
implant formation was reported as being dependant on
the polymeric state such as phase inversion, low-glass
transition temperature, or on hydrogels that formed by the
aid of cross-linking reagents and chemo- or thermosensi-
tazation [98, 99]. In addition, the system could deliver drug
directly or indirectly to the targeted sites, through subcu-
taneous injection and/or intratumoral injection (Figure 7)
[93]. Overall, the semisolid temporary depots oﬀer sev-
eral advantages such as enhanced local drug retention,
sustained release, and potential for long-term storage.
However, repeated injections and passive drug release are
still a factor that limits their use as ideal pharmaceutical
carriers.
3.2. Prefabricated Polymeric Scaﬀolds. Prefabricated poly-
meric scaﬀolds have gained a lot of attention as depots for
delivery of bioactive molecules, regenerative cells, growth
factors, and pre-encapsulated bioactive loaded liposome
[100, 101]. Unlike injectable in situ scaﬀolds in which a
semisolid scaﬀold is achieved after injection, prefabricated
polymer scaﬀold solid depot materials are formed outside
the body, then surgically implanted [102]. In additional,
pre-fabrication polymeric scaﬀold can be designed to meet
the required characteristics of an ideal scaﬀold. Desir-
able attributes of an ideal scaﬀold are: three-dimensional
structure, appropriate surface chemistry, fabrication from
materials which are biodegradable or bioresorbable, should
not induce any adverse response, scaled pore capacity, and
highly reproducible shapes and size [99, 101]. Diﬀerent
fabrication techniques have been used to achieve the above
criteria, such as ﬁber bonding, emulsion freeze drying,
solvent casting, high-pressure processing, gas foaming, and
electrospinning [102–105]. Various polymers that have been
researched for this application are either biodegradable or
nondegradable, synthetic or natural, or a combination of
the two [9, 106]. The major challenge of prefabricated
polymeric scaﬀoldsis thata nondegradable polymeric device
requires surgical removal at the end of treatment, which
is often known to be associated with pain [107]. However,
the beneﬁt on sustained release for the pre-encapsulated
drug loaded scaﬀold over a long period of time has been
reported and declared successful [96]. Stenekes and cowork-
ers [8] demonstrated that liposome embedded inside a
biodegaradbledepotpolymericscaﬀoldwasabletosustained
drug release over a prolonged period of time (Figure 8).
In addition, the released liposome was found intact after
many days storage within the inside depot polymeric
scaﬀold.
4.NaturalProduct-BasedLiposomalDrug
Delivery Systems
4.1. Collagen-Based Liposomal Drug Delivery Systems. Col-
lagen is a major natural protein component in mammals
that is fabricated from glycine-proline-(hydroxy) proline
repeats to form a triple helix molecular structure [84]. So
far, nineteen types of collagen molecules have been isolated,
characterized, and reported in both medical and pharma-
ceutical applications [108–110]. Collagen has been widely
used in pharmaceutical applications due to the fulﬁllment of
many requirements of a drug delivery system such as good
biocompatibility, low antigenicity, and degradability upon
implantation[111].Furthermore,collagengelsare oneofthe
ﬁrst natural polymers to be used as a promising matrix for
drug delivery and tissue engineering [112]. Biodegradable
collagen-based systems have served as 3D scaﬀold for cell
culture, survival of transfected ﬁbroblasts, and gene therapy
[81, 113]. In this case, collagen scaﬀolds were fabricated
through introducing various chemical cross-linking agents
(i.e., glutaraldehyde, formaldehyde, carbodiimide) or by
physical treatments (i.e., UV irradiation, freeze-drying, and
heating) [109, 114–117]. The combination of liposomes and
collagen-based technologies has been long achieved since
the early 80s [112]. In this case, drugs and other bioactive
agents were ﬁrstly encapsulated in the liposomes and then
embedded inside a depot composed of collagen-based sys-
tems, including scaﬀolds and gels. The combination of these
two technologies (i.e., liposomes and collagen-based system)
has improved storage stability, prolonged the drug release
rate, and increased the therapeutic eﬃcacy [84, 118, 119].
In addition, a study that was conducted by Marston et al.
[120], demonstrated that temperature sensitive liposomes
and collagen may thermally trigger the release of calcium
and phosphate salts. Multiple collagen-based system for
pharmaceutical carriers or medicinal applications are cur-
rently available for clinical purposes [121]. Figure 9 depicts
a schematic representation of collagen-based liposome.
4.2. Gelatin-Based Liposomal Drug Delivery Systems. Gelatin
is a common natural polymer or protein which is normally
produced by denaturing collagen [122]. It has been used in
pharmaceuticalandmedicalapplicationsduetoitsoutstand-
ingpropertiessuchasbiodegradability,biocompatibility,and
low antigenicity [100]. In addition, gelatin can be easy to
manipulateduetoitsisoelectric pointthatallowsittochange
from negative to positive charge in an appropriatephysiolog-
ical environment or during the fabrication, a property that
has found it being very attractive to many pharmaceutical
researchers [123]. Gelatin is one of the natural polymers
used as support material for gene delivery, cell culture,
and more recently tissue engineering. Gelatin-based systems
have the ability to control release of bioactive agents such
as drugs, protein, and dual growth factors [95, 100, 124].
It has been reported that it is possible to incorporate
liposome-loaded bioactive compounds into PEG-gelatin gel
which function as porous scaﬀold gelatin-based temporary
depots with controlled drug release over prolonged periodsJournal of Drug Delivery 7
Targeting ligand
& stealth facility
DNA-liposome complex
Translocation to nucleus
Membrane receptors
(4)
Endosomal escape
and complex dissociation
(3)
Endosomal uptake (2)
Binding ligand/receptor (1)
Figure 6: A schematic depicting the optimization of liposomal gene delivery (source: Uchegbu [74]).
of time [125, 126]. However, some setbacks have been
identiﬁed, and they are said be associated with the use
of gelatin-based systems in pharmaceutical applications.
These setbacks include poor mechanical strength and inef-
fectiveness in the management of infected sites [108]. A
combination of a collagen-based system with liposomes has
been proposed to achieve the stability of the system and
controlled release proﬁles of the incorporated compounds.
The success of these formulations, (i.e., gelatin, hydrogel,
and scaﬀolds) was enhanced by cross-linking agents such as
glutaraldehyde, sugar, and enzyme transglutaminase. It was
also discovered that the cross-linking density of gelatin was
able to aﬀect the rate of degradation and rate of bioactive
agents release from gelatin vehicles or from liposomes
embedded inside gelatin-based systems [127–130]. Another
s t u d yb yP e p t ua n dc o w o r k e r s[ 83] reported a controlled
release of liposome-encapsulated calcein ﬂuoroscence dye
or calcein labeled with rhodamine from temporary depot
of gelatin-based system which is made up of Gelatin-
carboxymethylcellulose ﬁlms. In the same study, the release
rate of loaded liposome was found to depend mostly on
the quantity of liposomes entrapped inside the ﬁlms, degree
of swelling of the ﬁlm, ﬁlm network density, and the ﬁlm
geometry which was supported by glutaraldehyde cross-
linkingagents.Inasimilar study,DiTzioandcoworkers[125]
demonstrated the successof preventionof bacterial adhesion
to catheters by ciproﬂoxacin-loaded liposomes which were
entrapped inside a poly(ethylene glycol-)gelatin hydrogel.
Another study by Burke and coworkers [126]d e m o n s t r a t e d
that there was a successive release of oxidizing reagent
(sodium periodate) from thermal liposome entrapped inside
a stimuli-responsive gelatinous derivative hydrogel. In gen-
eral, the combination of collagen with liposome has been
reported to improve liposome stability and the controlled
release of incorporated bioactive agents within liposome
formulations.
4.3. Chitosan-Based Liposomal Drug Delivery Systems. Chi-
tosan is a natural linear bio-polyaminosaccharide polymer
obtained by N-deacetylation of chitin, which is fabricated
from the exoskeleton of marine crustaceans such as shrimps,
crabs, prawns, and fungi [87, 131]. It has been broadly
investigated in pharmaceutical applications as a bioactive
molecule delivery method or as depot of pharmaceutical
carriers due to its desirable properties such as mucoadhe-
siveness, biodegradability, biocompatibility, and nontoxicity
[132–135]. The combination of chitosan with liposome
technologies is considered as being a promising approach
in the drug delivery arena. More recently, chitosan tech-
nology has been reported as being a depot for liposomal
drug delivery systems in the form of porous hydrogel or
scaﬀold. Chitosan-based hydrogels were generate with or
without a cross-linking agent such as glutaraldehyde or by
interacting with diﬀerent types of divalent and polyvalent
anions [12, 136, 137]. Novel in situ gelling formulations
of hydrogels such as thermosensitive and mucobioadhesive8 Journal of Drug Delivery
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Figure7:Schematicdepicting drugdeliveryfrompre-encapsulated drug-loadedliposomesincorporatedwithinaninjectablehydrogel-based
system (adapted from Ta et al. [93]).
hydrogels have been recently been proposed as a depot
for liposomes for sustained drug release over a prolong
period of time [12, 138]. Chitosan scaﬀold matrix can be
fabricated with unique structure by simple approaches such
lyophilization technique, by use of crosslinked agents of
chitosan solution/hydrogels followed by incubation in the
liquid nitrogen, or by employing liquid carbon dioxide,
solid-liquid separation, and, most recently, supercritical
immersion precipitation techniques [11, 139–141]. Drugs
such as cytarabine that have been pre-encapsulated in
liposomes and then incorporated within chitosan hydrogels
have been provento be suitable model for drug delivery with
sustained drug release in vivo at body temperature [12].
4.4. Fibrin-Based Liposomal Drug Delivery Systems. Fibrin
is a biodegradable polymer obtained by polymerization of
ﬁbrinogen in the presence of thrombin enzyme [142]. The
concept of developing ﬁbrin-based technology as a tempo-
rary depot in both pharmaceutical and bioengineering ﬁelds
has received considerable attention over the past decades
[82, 143] .T h eu n i q u ep r o p e r t i e so ft h eﬁ b r i n - b a s e ds y s t e m s
such biodegradability and nontoxicity, have been reported
to inﬂuence the delivery eﬃciency of growth factors, genes,
proteins, various cells and drugs [144–150]. The fabrication
of semirigid ﬁbrin scaﬀold upon injection has been achieved
under physiological conditions at the site of interest with
rapid polymerization [147]. Furthermore, ﬁbrin scaﬀolds
have also been used as temporary depots for drug delivery
vehicles by incorporation of drug-loaded liposomes alone,
or by incorporation of liposomes into a chitosan matrix
(containing bioactive agent molecules such as protein, drugs
and genes) within the depot composed of the ﬁbrin-based
systems. The combination of two widespread devices, ﬁbrin
and liposome technologies, resulted in sustained bioactive
agent release over prolonged periods of time [11, 146, 150–
152].
4.5. Alginate-Based Liposomal Drug Delivery Systems. Algi-
nate also serves as an example of a naturally occurring
linear polysaccharide. It is extracted from seaweed, algae,
and bacteria [153–155].The fundamental chemical structure
of alginate is composed of (1–4)-b-D-mannuronic acid (M)
and (1–4)-a-L-guluronic acid (G) units in the form of
homopolymeric (MM- or GG-blocks) and heteropolymeric
sequences (MG or GM-blocks) [156]. Alginate and their
derivates are widely used by many pharmaceutical scientists
for drug delivery and tissue engineering applications due
to its many unique properties such as biocompatibility,
biodegradability, low toxicity, non-immunogenicity, water
solubility, relatively low cost, gelling ability, stabilizing prop-
erties, and high viscosity in aqueous solutions [157, 158].
Since alginate is anionic, fabrication of alginate hydrogels
has successively been achieved through a reaction with
cross-linking agents such as divalent or trivalent cations
mainly calcium ions, water-soluble carbodiimide, and/or
glutaraldehyde [159]. The cross-linking methodology was
conducted at room temperature and physiological pH [160].
Thesuccessin fabricatinghighlyporous3Dalginatescaﬀolds
has been through lyophilization [161]. Thus far, alginate-
based systems have been successfully used as a matrix for
the encapsulation of stem cells and for controlled release of
proteins, genes, and drugs [162–166]. In addition, alginate-
based systems have been used as depots for bioactive agent-
loaded liposomes, for slow drug release [9, 167]. Highly
increased eﬃcacy has been reported from these integrated
deliverysystems when comparedtopolymeric-based systems
or liposome-based systems alone [168, 169]. Machluf and
coworkers [170] have reported radio labeled protein release
from liposomes encapsulated within microspheres of the
calcium-crosslinked alginate. Another study by Hara and
Miyake [171] demonstrated the release of Calcein (which
is a ﬂuorescent dye) and Insulin from calcium alginate gel-
entrapped large multilamellar liposomal vesicles in vivo.
4.6. Dextran-Based Liposomal Drug Delivery Systems. Dex-
tran is a natural linear polymer of glucose linked by a 1–
6 linked-glucoyranoside, and some branching of 1,3 linked
side-chains [172]. Dextran is synthesized from sucrose byJournal of Drug Delivery 9
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Figure 8: Schematic depicting drug delivery from pre-encapsulated drug-loaded liposomes incorporated within a prefabricated polymeric-
based depot system with eventual entry through a cell membrane (adapted from Stenekes et al. [8]).
certain lactic-acid bacteria, the best-known being Leuconos-
toc mesenteroides and Streptococcus mutans.T h e r ea r et w o
commercial preparations available, namely dextran 40 kilo-
daltons (kDa) (Rheomacrodex) and dextran 70 Kilodaltons
( k D a )( M a c r o d e x )[ 173, 174]. In pharmaceutics, dextran
has been used as model of drug delivery due to its unique
characteristics that diﬀerentiate it from other types of
polysaccharide. This include water solubility, biocompatibil-
ity, and biodegradability [175]. In recent studies, dextran
has been regarded as a potential polysaccharide polymer
that can sustain the delivery of both proteins, vaccines, and
drugs [176–179]. Interleukin-2, which is a highly eﬀective
anticancer drug, is among the success obtained in delivering
a combination of drug-loaded liposome and injectable
dextran hydrogel [180]. Injectable and degradable dextran-
based systems for drug delivery were generated by a cross-
linking reaction with photo-polymerization or free radical
polymerization [181]. In another study by Yeo and Kohane
[182], it was demonstrated that it is possible to fabricate
dextran-based hydrogel using dextran derivatives such as
carboxymethyldextran derived by aldehyde-modiﬁcation or
carboxymethylcellulose. In the same study, dextran-based
systems were reported to inhibit peritoneal adhesions due
to cytotoxicity. Cytotoxicity study was demonstrated in
mesothelial cells and macrophages, and it’s reported to
be associated with a crosslinked agent [182]. A study by
Stenekes and coworkers [8] demonstrated the successive
encapsulation of a drug-loaded liposome depot into a dex-
tran polymer-based material. The polymeric-based materials
were fabricated using a two phase system, the ﬁrst phase was
water and poly(ethylene glycol) and the second one water
methacyrlated dextran. The slower degradation of dextran
polymeric material resulted in sustained liposome release
overa period of100days [8]. Liposomes released from depot
were reported to be intact, and there was no signiﬁcant
change in liposomal size. In a gene therapy study by Liptay
and coworkers [183], it was reported that recombinant
DNA (which contains chloramphenicol acetyltransferase)
was successively encapsulated in cationic liposomes and then
integrated within dextran. This system was reported to be
a suitable delivery system since it could stop transfection
eﬃciency within the colon epithelium wall in vivo [183].
5.LiposomalDrug DeliverySystemsBased on
SyntheticPolymers
5.1. Carbopol-Based Liposomal Drug Delivery Systems. Car-
bopol hydrogel formulation is a synthetic type of hydro-
gel, which is a polyacrylic acid derivative. Carbopol 980,
Carbopol 974NF resin, and Carbopol 940 have been widely
used as pharmaceutical carriers due to their outstanding
properties such as bioadhesivity, biocompatibility, and low
toxicity [184–186]. Carbopol can swell quickly in water
and adhere to the intestinal mucus because the functional
carboxylicacidgroups(–COOH)canformhydrogenbridges
to interpenetrate the mucus layer [187, 188]. Furthermore,
carbopol can inhibit the activity of the dominant enzymes in10 Journal of Drug Delivery
the gastrointestinal tract due to the possession of carboxylic
groups in its structure [187]. In a study that was conducted
by Tang and coworkers [186], the formulation of Carbopol
containing superporous hydrogel composites showed that
swelling was duetoionic strengthin salt,sensitive atdiﬀerent
pH values. In recent studies, Hosny [189, 190]r e p o r t e d
thepossibilityofincorporating drug-loadedliposomewithin
Carbopol hydrogel-based system which acted as a temporary
depot. They conducted the study in vitro with the aim
of improving low viscosity and poor sustainability release
over a prolonged period of time, which is associated with
liposome setbacks. The results suggested that the degree
of encapsulation and prolongation of drug release rate of
either drugs or loaded liposomes in temporary depots of
Carbopol depends to a great extent on the properties of the
vesicles, such as charge and rigidity. Various drugs such as
ciproﬂoxacin and galiﬂoxacin have been reported to have
been employed in this system, by ﬁrstly being encapsulated
within liposomes and then integrated within the temporary
depot of the Carbopol-based system. These studies revealed
that loaded liposome integrated within Carbopol-based
system was a suitable model of drug delivery for both ocular
and vaginal disorders [189–192].
5.2.PolyvinylAlcohol-BasedLiposomalDrugDelivery Systems.
Polyvinyl alcohol (PVA) is a water soluble highly hydrophilic
synthetic polymer, with a molecular mass of 80 killodaltons
(KDa). PVA can be used in a widely range of applications
such industrial, commercial, medical, and food products
[193, 194]. In addition, PVA has gained a lot of attention in
pharmaceutical applications due to some attractive proper-
ties such as low toxicity, excellent ﬁlm-forming, biodegrad-
ability, emulsifying capacity, biocompatibility, and adhesive
properties [195, 196]. PVA-based hydrogel or scaﬀolds have
been fabricated using chemical cross-linking agents such as
citric acid derivative, glutaraldehyde, and formaldehyde, or
by physical cross-linking processes such as ultraviolet photo-
cross-linking, freezing-thawing, and radiation [126, 197,
198]. Various studies have been performed on the eﬀects of
PVA-based polymers on the release rate of pre-encapsulated
drug-loaded liposomes. In these combination systems, PVA
was postulated to enhance liposome viscosity, making them
more stable and less permeable, thus providing a sustained
release liposomal delivery system [185]. A recent study
conductedby Litvinchuk and coworkers [199]d e m o n s t r a t e d
that the success of calcein-loaded liposome embedded inside
a temporary depot was inﬂuenced by photocross-linking.
In the same study, the ﬂuorescence intensity was reported
to result in a sustained release eﬀect as observed from
day 0 to 120, in both phosphate buﬀer saline and blood
plasma in vitro. Overall, the study demonstrated that PVA
as a temporary depot oﬀers several advantages to liposome
delivery systems. These include liposome stability, viscosity,
and sustained drug release over prolonged periods of time.
Ciproﬂoxacin, a synthetic chemotherapeutic antibiotic was
amongthedrugsthatwere reported tohavebeensuccessfully
integrated into liposome and PVA-based delivery systems
[185].
6.TechniquesforEmbedding Drug-Loaded
LiposomeswithinDepot Polymeric-Based
Systems
Diﬀerent techniques of loading the drug within temporary
depot polymeric-based systems either by using natural or
synthetic polymers have been reported by many researchers
[8, 11, 12, 118, 185]. However, several disadvantages were
found to be associated with this approach such as loss
of the eﬃcacy of the drugs during the fabrication process
due to the acidic, basic, and/or toxic eﬀect of the solvents
employed, heat of sonication, or biochemical interactions
with polymeric-based materials such human ﬁbrin gel [11,
200]. To avoidthese setbacks, new techniques were suggested
by ﬁrstly pre-encapsulating the drugs within liposome
and then embedding the drug-loaded liposome into the
temporary depot polymeric-based system. This approach
attracted many researchers as it improved drug delivery
and at the same time preserved drug bioactivity [11, 36,
185, 189, 201]. The success of this technique was also
reported after pre-encapsulating drug-loaded liposomes into
ﬁbrinogen solution, then injecting the mixture into porous
chitosan ﬁlms [11, 201]. Another approach using synthetic
PVA was made in which thin ﬁlms of liposomes were
hydrated above their glass transition temperature together
with PVA as the hydration solution in order to enhance
liposome entrapment into the temporary depot of PVA-
based system [185]. Thermosensitive hydrogel was also
investigatedusingachitosan derivative,which istemperature
sensitive. In this case, drug-loaded liposome was mixed
with prechilled solutions of chitosan solution until an iso-
osmotic pressure was achieved within the chitosan solution
[12]. In another study that was conducted by Gobin and
coworkers [36], it was demonstrated that drug-loaded lipo-
somes were incorporated within a polymeric-based system
with agitation and subsequently lyophilized after being
frozen overnight at −80◦C. Tabandeh and Aboufazelia [118]
suggestedanitrogenrefrigerationapproach. Inthiscase, pre-
encapsulated drug-loaded liposomes were mixed together
with collagen solution and then frozen in liquid nitrogen
for 24 hours. Since soluble collagen was used in this study,
adequate concentrations of collagen were suggested in order
to facilitate the drug release and avoid the chain mobility
associated with collagen.
A more recent study has demonstrated an enhanced pro-
cess of drug-encapsulated liposome into Carbopol hydrogel
by using deionized water as a vehicle (i.e., employing a
hydration approach) [189]. This involved the development
of an eﬀective prolonged-release liposomal hydrogel for-
mulation containing ciproﬂoxacin for ocular therapy. Drug
delivery in ocular therapy has for long been a diﬃcult task
to accomplish because of the poor drug bioavailability that
is mainly due to the precorneal loss factors. These factors
include tear dynamics, insuﬃcient residence time in the
conjunctival sac, and nonproductive absorption [185, 202].
Thus far, ﬂuoroquinolones have shown excellent activity
against most of the frequently occurring Gram-positive and
Gram-negative ocular pathogens [189]. Earlier generations
of ﬂuoroquinolones (e.g., oﬂoxacin) were often encounteredJournal of Drug Delivery 11
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Figure 9: A schematic representation of a collagen-based liposome (source: Kang et al. [121]).
with a problem of developing resistance at a fast rate [203,
204]. Ciproﬂoxacin is active against a broad spectrum of
aerobic Gram-positive and Gram-negative bacteria. Resis-
tance to this drug develops slowly and has shown to cause
a minimal toxicity [189]. It is currently the drug of choice
as an anti-infective ocular agent [205, 206]. Eﬃcacy of
the marketed ophthalmic ﬂuoroquinolone products, mostly
aqueous solutions, is limited by poor ocular bioavailability,
compelling the frequent dosing regimen, and uncompro-
mised patient compliance [207, 208]. Thus, prolonged-
release ciproﬂoxacin liposomal hydrogel has proven to be a
suitable delivery system for ocular infections.
7.ModulatingDrugReleasefromLiposomes
withinPolymericDepot Systems
Sustainedreleaseoftherapeuticallyactivecompoundsloaded
with liposome in a depot incorporated into polymeric-based
systemoﬀersthepossibilityofreducingthedosingfrequency,
which may lead to the reduction of side eﬀects and therefore
sustained drug action [12]. A study that was conducted
by Machluf and coworkers [170]d e m o n s t r a t e dt h a tr a d i o -
labeled protein-loaded liposomes couldbe embedded within
two membrane layers of a polymeric-based system such as
calcium cross-linked alginate and alginate integrated with
poly(l-lysine) for sustained release of radio-labeled bovine
serum albumin both in vitro and in vivo. In another set
of studies, it was postulated that the success of liposome
release from polymeric-based systems could be due to mesh
size of the matrix, size of liposome, diﬀusion, chemical,
pH, and/or enzyme factor [8, 82, 112, 209]. In yet another
s t u d yb yD h o o ta n dW h e a t l e y[ 168], liposome release
from barium-alginate depots was reported to be inﬂuenced
by the cross-linking ions. Leakiness of liposomes during
the encapsulation process was due to high lipid content
(i.e., cholesterol) during liposome fabrication for which
a high liposomal escape was also observed. In comparing
the liposome and degradable system to the liposome and
nondegradable polymer-based systems, the results indicated
that the liposomal release for the ﬁrst system was due
to degradation of the polymeric matrix, while for the
second system an insuﬃcient release was observed during
the same period of study [210]. Nixon and Yeung [164]
conducted a study together with Stenekes and coworkers
[8] in which they could demonstrate that liposomes with
low and high membrane ﬂuidity were successfully released
from a polymeric-based system in their intact form and
with preserved size for approximately 60 days. Although pre-
encapsulated drug-loaded liposome could show controlled
drug release from the depot, majority of these studies have
shown that the obtained drug release proﬁles depended to a
greater extent on the liposomal burst eﬀect rather than the
diﬀusion process [11, 170, 201].
8.The Successesand ChallengesEmerging
fromCompositeLiposomeand
Polymeric-Based Technologies
The combination of liposome-based system and polymeric-
based system for sustained release of therapeutically active
compounds has been demonstrated to be successful in
pharmaceuticalapplications.Sustainedreleaseproﬁlesofdif-
ferent bioactive molecules such as gene, drugs, protein, and
growth factor from liposome encapsulated in both natural
or synthetic biodegradable polymeric material have been
obtained [12, 169, 171]. The success of this drug delivery
combination depends mostly on encapsulation eﬃcacy and
the type of drug release proﬁle that is obtained. Eﬃciency
in encapsulating drug-loaded liposome was reported to be
dependentonseveraltechniques,suchascross-linkingagents
(glutaraldehyde, formaldehyde, carbodiimide) or physical12 Journal of Drug Delivery
treatments (i.e., UV irradiation, freeze-drying), during fab-
rication process [152, 160]. Sustained release kinetics of the
pre-encapsulated drug-loaded liposome depends most on
the degradation rate of the polymeric materials. This system
has added a remarkable advantage to both technologies
(i.e., liposome-based and polymeric-based), though more so
to the liposome technology since polymeric materials are
more stable than liposomes. The following properties were
achieved by embedding the liposomes into a polymeric-
based system: (i) sustained release over prolonged periods
of time, (ii) improved viscosity, (iii) stability of liposome,
and (iv) improved half-life for both the drugs and liposome.
In polymeric-based system incorporated with liposomes,
drug delivery eﬃcacy and preservation of drug bioactivity
has been achieved. This is due to the fact that liposomes
have a higher degree of biocompatibility when compared
to polymeric materials [8, 36]. Although this composite
system demonstrated improved success, there are still some
major challenges that need to be overcome. Incorporation of
toxic organic solvent or high heat during fabrication process
can inhibit the activity of some bioactive molecules such as
protein [11, 200]. Furthermore, since drug-loaded liposome
release proﬁles seem to depend most on degradation of
polymeric materials, majority of drug-loaded liposome may
remain enmeshed within the depot or insuﬃcient initial
release at commencement of treatment may be a problem.At
the same time, high overdose may occur during high degra-
dation period. In either case, degradable polymeric material
has demonstrated more eﬃcacy than nondegradable poly-
meric material since with the latter depot, insuﬃcient drug
release was reported [210].
9.FuturePerspective
Signiﬁcant development has been reported on combination
of the liposome-based technology with temporary depot
polymeric-based technology in sustaining drug release over
prolonged periods of time. However, combination of both
drug delivery technologies into a single model of drug
delivery has been reported to be associated with inad-
equate drug release. Since both materials can be easily
manipulated, design of a new ideal temporary depot of
the polymeric-based technologies to enhance therapeutic
eﬃcacy or improve the drug release proﬁle is of a great
interest.Integrationofthemoreadvancedtypesofliposome-
based technologies such as targeted- or stimuli-sensitive
liposomes in this system can enhance therapeutic eﬃcacy.
In addition, targeted liposome formulations, with targeted
moieties such as antibodies, peptide, glycoprotein, polysac-
charide, growth factors, carbohydrate, and receptors may
increase liposomal drug accumulation in the tissues/cells via
overexpressed receptors, antigen, and unregulated selectins.
Sensitivity of liposomes to pH, light, magnetism, tem-
perature, and ultrasonic waves can enhance therapeutic
eﬃcacy. Some polymeric systems have demonstrated some
disadvantages in this application such as nondegradability
that results in insuﬃcient drug release. The use of a combi-
nation liposomal-based system with natural and/orsynthetic
polymeric biodegradable and/or nondegradable polymers
may add strength to the depot while improving liposomal
release proﬁle. Although organic solvent are normally added
during fabrication, nontoxicityshould be rigorously assessed
in ex vivo studies. In summary, the combination system, as
a model of sustained release of drug-loaded liposome from
temporary polymeric depots, has been declared successful
but system improvements are demanded. Since this system is
implantable, it may be useful in future for the management
of chronic diseases such as Aid Dementia Complex, Tuber-
culosis, Cancer, or Neurodegenerative disorders, such as
Parkinson’s and Alzheimer’s disease, which normally require
regular doses over prolonged periods of time.
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